TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29524918

Group type: EXPERIMENTAL
Intervention: Working memory task with emotional distractors (happy and fearful) during 2-back task
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: fMRI analysis of brain activity in left IFG (BA 45)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Working memory task with emotional distractors (happy and fearful) during 0-back task
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cognitive training for emotion regulation
Number of subjects: 20
Study: 29525290

Group type: EXPERIMENTAL
Intervention: Peer-enhanced intervention
Number of subjects: 193

Group type: COMPARATOR
Intervention: Active cognitive-behavioral weight loss intervention
Number of subjects: 193
Study: 29525512

Group type: EXPERIMENTAL
Intervention: Bioimpedance analysis (BIA)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Follow-up at 6 and 12 months
Number of subjects: 200
Study: 29525541

Group type: EXPERIMENTAL
Intervention: Chemohormonal therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29525724

Group type: EXPERIMENTAL
Intervention: Invasive strategy (coronary angiogram and revascularization if anatomically amenable)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Conservative strategy (medical treatment and coronary angiogram only if persistent clinical instability)
Number of subjects: 178
Study: 29525775

Group type: EXPERIMENTAL
Intervention: Individualised, supervised exercise (six weekly sessions)
Number of subjects: 0
Study: 29525782

Group type: EXPERIMENTAL
Intervention: Chest pain units
Number of subjects: 2520
Study: 29526614

Group type: EXPERIMENTAL
Intervention: Elosulfase alfa 0.1 mg/kg/week
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Elosulfase alfa 1.0 mg/kg/week
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Elosulfase alfa 2.0 mg/kg/week
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Elosulfase alfa (home infusions)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Elosulfase alfa (overall)
Number of subjects: 20
Study: 29526687

Group type: EXPERIMENTAL
Intervention: Venous pressure gradients (VPGs)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: FCG-rh (femorocaval gradient after reactive hyperemia)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Femoral vein pressures at rest and after reactive hyperemia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of FCG-rh
Number of subjects: 50
Study: 29527010

Group type: EXPERIMENTAL
Intervention: Veliparib (200 mg BID) plus FOLFIRI (without 5-fluorouracil bolus)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Veliparib (10-270 mg BID, days 1-5, 15-19) and FOLFIRI (days 1-3, 15-17)
Number of subjects: 92
Study: 29527344

Group type: EXPERIMENTAL
Intervention: CHW-led intervention
Number of subjects: 108
Study: 29527350

Group type: EXPERIMENTAL
Intervention: mCME V.2.0 intervention (daily SMS quizzes, readings, online CME links, feedback)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: mCME V.2.0 intervention
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (equal access to online CME courses)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study: 29527358

Group type: EXPERIMENTAL
Intervention: Centrally produced ready-to-use therapeutic food
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Locally produced ready-to-use therapeutic food
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Augmented, energy-dense, home-prepared food
Number of subjects: 906
Study: 29527644

Group type: EXPERIMENTAL
Intervention: Make Safe Happen® app
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-injury-related app
Number of subjects: 0
Study: 29527652

Group type: EXPERIMENTAL
Intervention: Lung ultrasound
Number of subjects: 62

Group type: COMPARATOR
Intervention: Chest X-ray
Number of subjects: 62
Study: 29528048

Group type: EXPERIMENTAL
Intervention: Biomarker-guided treatment shortening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard TB treatment
Number of subjects: 0
Study: 29528727

Group type: EXPERIMENTAL
Intervention: B vitamin intake assessment through 24-hour dietary recalls
Number of subjects: 0
Study: 29528761

Group type: EXPERIMENTAL
Intervention: Raman spectroscopy of PBMCs
Number of subjects: 48
Study: 29529007

Group type: EXPERIMENTAL
Intervention: Urinary AKI biomarkers (TIMP-2*IGFBP-7 ≥0.78 at 12 hours)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Urinary AKI biomarkers (KIM-1 ≥529.57 at 24 hours)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Milrinone clearance in patients with AKI
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Excessive milrinone activity
Number of subjects: 94
Study: 29529091

Group type: EXPERIMENTAL
Intervention: Ramadan fasting (RF) with aspirin
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control group (non-DM patients)
Number of subjects: 177
Study: 29529139

Group type: EXPERIMENTAL
Intervention: Fortified human milk
Number of subjects: 32
Study: 29529147

Group type: EXPERIMENTAL
Intervention: Higher-risk participants (AA genotype)
Number of subjects: 114
Study: 29529156

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (≥400 µg/d)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (elevated plasma folate)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 563
Study: 29529162

Group type: EXPERIMENTAL
Intervention: Cereal fiber
Number of subjects: 117885

Group type: EXPERIMENTAL
Intervention: Carbohydrate-to-cereal fiber ratio
Number of subjects: 117885

Group type: EXPERIMENTAL
Intervention: Starch-to-cereal fiber ratio
Number of subjects: 117885

Group type: EXPERIMENTAL
Intervention: Total fiber intake
Number of subjects: 117885

Group type: EXPERIMENTAL
Intervention: Carbohydrate-to-total fiber ratio
Number of subjects: 117885

Group type: EXPERIMENTAL
Intervention: Highest quintile of carbohydrate intake
Number of subjects: 117885
Study: 29529177

Group type: EXPERIMENTAL
Intervention: Performed revascularization
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Deferred revascularization
Number of subjects: 1334
Study: 29530029

Group type: EXPERIMENTAL
Intervention: Canadian CT Head Rule (CCHR) presentation
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Malpractice review information
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Patient cost information
Number of subjects: 167

Group type: COMPARATOR
Intervention: Initial imaging orders
Number of subjects: 167
Study: 29530053

Group type: COMPARATOR
Intervention: Neural stimulation system active during simulated collision events
Number of subjects: 7

Group type: COMPARATOR
Intervention: Neural stimulation system active during simulated rapid turns
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Neural stimulation system inactive (subjects acting as their own controls)
Number of subjects: 7
Study: 29530274

Group type: EXPERIMENTAL
Intervention: Cardiovascular risk factors (CVRF) assessment
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Dyslipidaemia prevalence
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Hypertension prevalence
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Diabetes prevalence
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Smoking prevalence
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Abdominal obesity prevalence
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) ≥30kg/m prevalence
Number of subjects: 410
Study: 29530544

Group type: EXPERIMENTAL
Intervention: tedizolid phosphate 200 mg, once-daily for 7-14 days
Number of subjects: 125

Group type: COMPARATOR
Intervention: linezolid 600 mg, twice-daily for 7-14 days
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: tedizolid phosphate 200 mg, once-daily
Number of subjects: 125

Group type: COMPARATOR
Intervention: linezolid 600 mg, twice-daily
Number of subjects: 125
Study: 29530644

Group type: EXPERIMENTAL
Intervention: Strong recommendations with evidence summaries
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Weak recommendations with evidence summaries
Number of subjects: 467

Group type: COMPARATOR
Intervention: Evidence summaries alone
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Strong recommendations
Number of subjects: 467
Study: 29530667

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks and axitinib 5 mg orally twice daily
Number of subjects: 55
Study: 29530726

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA
Number of subjects: 304
Study: 29530837

Group type: EXPERIMENTAL
Intervention: Surgical procedures with Staphylococcus aureus SSI
Number of subjects: 150000
Study: 29530855

Group type: EXPERIMENTAL
Intervention: Doripenem administration during dialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-hemodialysis dosing of Doripenem
Number of subjects: 0
Study: 29530914

Group type: EXPERIMENTAL
Intervention: MSD intervention consisting of 2-hour class sessions over a 13-week period
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 320
Study: 29530935

Group type: EXPERIMENTAL
Intervention: Trastuzumab treatment
Number of subjects: 0
Study: 29530989

Group type: EXPERIMENTAL
Intervention: First Blood Pressure Measurement (fBPM)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Short-term masked hypertension (STMH)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Short-term white coat hypertension (STWCH)
Number of subjects: 1000
Study: 29531316

Group type: EXPERIMENTAL
Intervention: Lenalidomide/RCHOP
Number of subjects: 427

Group type: COMPARATOR
Intervention: RCHOP alone
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Real-time ECPR
Number of subjects: 427

Group type: COMPARATOR
Intervention: Retrospective ECPR
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: RT-ECPR
Number of subjects: 427
Study: 29531651

Group type: EXPERIMENTAL
Intervention: Elotuzumab in combination with lenalidomide and dexamethasone (ELd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Ld)
Number of subjects: 0
Study: 29531754

Group type: EXPERIMENTAL
Intervention: Shared care cardiac rehabilitation (SC-CR)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Hospital-based cardiac rehabilitation (H-CR)
Number of subjects: 212
Study: 29531756

Group type: EXPERIMENTAL
Intervention: miRNA-8059
Number of subjects: 24

Group type: COMPARATOR
Intervention: CACS=0
Number of subjects: 24
Study: 29531765

Group type: EXPERIMENTAL
Intervention: sST2 as a continuous variable
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: sST2 in inflammatory and/or viral DCM subgroup
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: sST2 in idiopathic DCM subgroup
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: sST2 in multivariate model
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Galectin-3 as a continuous variable
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Galectin-3 in quartile model
Number of subjects: 262
Study: 29531766

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1212

Group type: COMPARATOR
Intervention: MED
Number of subjects: 1212

Group type: COMPARATOR
Intervention: CABG vs MED
Number of subjects: 1212
Study: 29531780

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 165
Study: 29531784

Group type: EXPERIMENTAL
Intervention: Verinurad (2.5-20 mg) plus allopurinol (300 mg once daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Allopurinol (300 mg once daily, 600 mg once daily, or 300 mg twice daily)
Number of subjects: 41
Study: 29531837

Group type: EXPERIMENTAL
Intervention: First-line panitumumab plus chemotherapy followed by second-line VEGFi
Number of subjects: 104

Group type: COMPARATOR
Intervention: First-line bevacizumab followed by second-line EGFRi
Number of subjects: 104
Study: 29531839

Group type: EXPERIMENTAL
Intervention: Adjuvant/neoadjuvant chemotherapy
Number of subjects: 289

Group type: COMPARATOR
Intervention: None (control group, did not receive chemotherapy)
Number of subjects: 289
Study: 29532104

Group type: EXPERIMENTAL
Intervention: GSK3008348, single doses of 1-3000 mcg administered by nebulisation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: GSK3008348, single doses of 300-3000 mcg administered by nebulisation
Number of subjects: 29
Study: 29532243

Group type: EXPERIMENTAL
Intervention: Multimodal healthy bone behaviors (HBB) education including a healthy bones prescription (BoneRx), face-to-face education, and customized educational materials.
Number of subjects: 103

Group type: COMPARATOR
Intervention: Routine care (control group).
Number of subjects: 103
Study: 29533307

Group type: EXPERIMENTAL
Intervention: Continuous video-EEG (cEEG) for 30 to 48 hours
Number of subjects: 348

Group type: COMPARATOR
Intervention: Routine EEG (rEEG)
Number of subjects: 348
Study: 29533369

Group type: EXPERIMENTAL
Intervention: MLE4901 (NK3R antagonist)
Number of subjects: 37
Study: 29533458

Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin (depatux-m) at a maximum tolerated dose (MTD) of 3.0 mg/kg.
Number of subjects: 56
Study: 29533507

Group type: EXPERIMENTAL
Intervention: Fluoroquinolone-resistant (FQ-R) E. coli strains
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Third-generation cephalosporin-resistant (3GC-R) E. coli strains
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Extended-spectrum β-lactamase (ESBL)-producing E. coli strains
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: International travel
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Use of antibiotics during the previous year
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: 3GC-R E. coli strains
Number of subjects: 359
Study: 29533531

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for 5 months
Number of subjects: 189
Study: 29533710

Group type: EXPERIMENTAL
Intervention: Dietary supplement (Blood Builder®/Iron Response®) containing 26 mg of iron, vitamin C, folate, and other nutrients, taken once daily for 8 weeks.
Number of subjects: 23
Study: 29533755

Group type: EXPERIMENTAL
Intervention: Canakinumab (4 mg/kg every 4 weeks)
Number of subjects: 301
Study: 29534064

Group type: EXPERIMENTAL
Intervention: AF genetic risk score (GRS)
Number of subjects: 904
Study: 29534170

Group type: EXPERIMENTAL
Intervention: Portico TAVI system
Number of subjects: 198
Study: 29534171

Group type: EXPERIMENTAL
Intervention: Childhood cancer survivors (CCS)
Number of subjects: 1002
Study: 29534198

Group type: EXPERIMENTAL
Intervention: 18F-FDOPA PET/CT
Number of subjects: 6

Group type: COMPARATOR
Intervention: CT/magnetic resonance imaging
Number of subjects: 6

Group type: COMPARATOR
Intervention: 68Ga-DOTA,Tyr3-octreotate PET/CT
Number of subjects: 6

Group type: COMPARATOR
Intervention: 18F-fluorodeoxyglucose PET/CT
Number of subjects: 6
Study: 29534240

Group type: EXPERIMENTAL
Intervention: Sleep quality (measured by Pittsburgh Sleep Quality Index [PSQI])
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Risk for obstructive sleep apnea (OSA; assessed by Berlin questionnaire)
Number of subjects: 1341

Group type: COMPARATOR
Intervention: Demographics and smoking history, disease severity (forced expiratory volume 1 s; 6 min walk test)
Number of subjects: 1341
Study: 29534336

Group type: EXPERIMENTAL
Intervention: Oral administration of prednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Partial GC receptor agonist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with systemic lupus erythematosus and rheumatoid arthritis
Number of subjects: 0
Study: 29534442

Group type: EXPERIMENTAL
Intervention: Infant formula, breastmilk, and infant cereals
Number of subjects: 2560

Group type: EXPERIMENTAL
Intervention: Breast-fed and mixed-fed infants
Number of subjects: 2560

Group type: COMPARATOR
Intervention: Formula-fed infants
Number of subjects: 2560

Group type: EXPERIMENTAL
Intervention: Energy intakes per day (kcal)
Number of subjects: 2560

Group type: EXPERIMENTAL
Intervention: Other main energy and carbohydrate sources
Number of subjects: 2560

Group type: EXPERIMENTAL
Intervention: Other main protein and total fat sources
Number of subjects: 2560
Study: 29534680

Group type: EXPERIMENTAL
Intervention: Brief Assessment Tool (BAT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Comprehensive Geriatric Assessment (C)
Number of subjects: 85
Study: 29534703

Group type: EXPERIMENTAL
Intervention: Transendoscopic enteral tubing (TET) procedure
Number of subjects: 86

Group type: COMPARATOR
Intervention: Training of general endoscopists
Number of subjects: 86
Study: 29534721

Group type: EXPERIMENTAL
Intervention: CVD 1208S (3 doses, 10 unspecified dosage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CVD 1208S
Number of subjects: 0
Study: 29535081

Group type: EXPERIMENTAL
Intervention: Strengths-based behavioral intervention via mobile app (Type 1 Doing Well)
Number of subjects: 82
Study: 29535141

Group type: EXPERIMENTAL
Intervention: Worsening renal function (WRF) defined as an absolute increase in creatinine of ≥0.3 mg/dL.
Number of subjects: 5625

Group type: EXPERIMENTAL
Intervention: Transient WRF defined as recovery of creatinine at discharge.
Number of subjects: 5625

Group type: EXPERIMENTAL
Intervention: Persistent WRF indicated by a nonrecovered creatinine level.
Number of subjects: 5625

Group type: EXPERIMENTAL
Intervention: Adverse in-hospital and follow-up outcomes associated with WRF.
Number of subjects: 5625
Study: 29535451

Group type: EXPERIMENTAL
Intervention: Naltrexone and Bupropion (NB32)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29535545

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ledipasvir for 12 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sofosbuvir plus oral weight-based ribavirin for 24 weeks
Number of subjects: 200
Study: 29535712

Group type: EXPERIMENTAL
Intervention: TLR4 agonist glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) with CN54gp140 vaccine, administered intramuscularly three times at 1-month intervals.
Number of subjects: 14
Study: 29535869

Group type: EXPERIMENTAL
Intervention: Smoothie drink with 2 grams of plant stanols (Nutrive Benecol®) and dietary advice
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control drink and dietary advice
Number of subjects: 99
Study: 29535915

Group type: EXPERIMENTAL
Intervention: Multidisciplinary care model
Number of subjects: 526

Group type: COMPARATOR
Intervention: Serial care arm
Number of subjects: 526
Study: 29536210

Group type: EXPERIMENTAL
Intervention: Septic shock patients
Number of subjects: 26

Group type: COMPARATOR
Intervention: Controls (children hospitalized for elective surgery)
Number of subjects: 26
Study: 29536342

Group type: EXPERIMENTAL
Intervention: Patient-Centered Methadone Treatment (PCM)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Typical Treatment Sessions
Number of subjects: 8
Study: 29536526

Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg once daily for non-Asian patients aged ≥ 6 years
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Eltrombopag 25 mg once daily for Asian patients, regardless of age
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Eltrombopag 25 mg once daily for all patients aged 1-5 years, regardless of ethnic origin
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Dose escalation at 2-week intervals or reduction as needed based on platelet counts
Number of subjects: 168
Study: 29536781

Group type: EXPERIMENTAL
Intervention: Tralokinumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29537178

Group type: COMPARATOR
Intervention: Respondent-driven sampling
Number of subjects: 1929

Group type: COMPARATOR
Intervention: Community-based recruitment
Number of subjects: 1929

Group type: COMPARATOR
Intervention: Online advertising
Number of subjects: 1929

Group type: EXPERIMENTAL
Intervention: Overall recruitment strategies
Number of subjects: 1929
Study: 29537325

Group type: EXPERIMENTAL
Intervention: oestradiol valerate/dienogest
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: ethinylestradiol/drospirenone
Number of subjects: 66

Group type: COMPARATOR
Intervention: healthy controls
Number of subjects: 66
Study: 29537444

Group type: EXPERIMENTAL
Intervention: 0.3% adapalene and 2.5% benzoyl peroxide gel plus oral doxycycline 100 mg twice daily
Number of subjects: 186
Study: 29537906

Group type: COMPARATOR
Intervention: Postoperative radiotherapy (RT) alone, n = 157
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Postoperative concurrent chemoradiotherapy (CRT), n = 153
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Both arms (RT and CRT)
Number of subjects: 321
Study: 29538667

Group type: EXPERIMENTAL
Intervention: Risk assessment without behavioral recommendations provided to the parent
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Close interpersonal ties among dyads
Number of subjects: 125
Study: 29538669

Group type: EXPERIMENTAL
Intervention: RET fusion-positive tumors
Number of subjects: 24

Group type: COMPARATOR
Intervention: RET negative tumors
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RET rearrangements
Number of subjects: 24
Study: 29538761

Group type: EXPERIMENTAL
Intervention: Low-frequency VMH-DBS
Number of subjects: 6
Study: 29539287

Group type: EXPERIMENTAL
Intervention: Symptomatic ZIKV infection
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Symptomatic ZIKV infection during first trimester
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Symptomatic ZIKV infection during second trimester
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Symptomatic ZIKV infection during third trimester
Number of subjects: 546
Study: 29540222

Group type: EXPERIMENTAL
Intervention: Apheresis treatment
Number of subjects: 6
Study: 29540225

Group type: EXPERIMENTAL
Intervention: Weekly iron and/or folic acid supplementation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Trial provision of free treatment
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Community education about the value of iron supplementation
Number of subjects: 39
Study: 29540234

Group type: EXPERIMENTAL
Intervention: Polycap DS® (containing aspirin 100 mg, atenolol 50 mg, ramipril 5 mg, thiazide 12.5 mg, simvastatin 20 mg) taken as two capsules once daily for 12 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care (UC) with separate, individual secondary preventive medications prescribed at the physician's discretion
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Polycap DS®
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 120
Study: 29540419

Group type: EXPERIMENTAL
Intervention: Work Task Motivation Scale for Teachers (quantitative phase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-depth interviews (qualitative phase)
Number of subjects: 0